Amit Munshi
Amit Munshi's purchase track record
How the stock did after each of Amit Munshi's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/21/2024 | IKT | $500K | +26.6% | -14.9% | -11.9% |
| 4/22/2024 | ZURA | $500K | +7.8% | +45.9% | +16.8% |
| 6/5/2023 | ZURA | $500K | +5.9% | -26.8% | +6.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
Inhibikase Announces Nasdaq Inducement Grants. Inhibikase Therapeutics disclosed that it granted inducement awards under Nasdaq Listing Rule 5635(c)(4). This type of grant is typically used to attract or retain new employees without requiring a shareholder vote. The company's stock is currently trading near its 52-week low, with an average analyst target of $6.00.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Zura Bio Named Top Pick by Guggenheim Amid Recent Price Gains. Zura Bio was highlighted as a top pick by Guggenheim, contributing to its recent upward movement alongside other stocks. The company's share price has risen, though it remains well below the average analyst target of $18.00. Current trading levels sit near the lower end of its 52-week range, reflecting a significant gap between current market price and long-term valuation estimates.
Transaction History
| ARQT | ▲ Buy | Grant | 5,778 | $0 | 6/5/2026 | View on chart |
| IKT | ▼ Sell | Other | 19,089 | $0 | 2/21/2026 | View on chart |
| ARQT | ▲ Buy | Grant | 2,021 | $0 | 12/4/2025 | View on chart |
| IKT | ▲ Buy | Grant | 57,265 | $0 | 2/21/2025 | View on chart |
| IKT | ▲ Buy | Open Market | 365,000 | $500K | 10/21/2024 | View on chart |
| ZURA | ▲ Buy | Open Market | 159,744 | $500K | 4/22/2024 | View on chart |
| ZURA | ▲ Buy | Open Market | 117,647 | $500K | 6/5/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
ARQT Highlights New ZORYVE Data, Wins Beauty Award, Faces Downgrade
Arcutis Biotherapeutics presented fresh clinical data for its topical drug ZORYVE at the EADV and Fall Clinical conferences, adding real‑world evidence on its use for inflammatory skin conditions. The company also received a 2026 Marie Claire Beauty Award for ZORYVE, highlighting its potential beyond dermatology. Meanwhile, analysts have downgraded the stock, citing a shrinking valuation multiple. These developments suggest the market is reassessing the company’s growth prospects.
ARQT Highlights New ZORYVE Data, Wins Beauty Award, Faces Downgrade. Arcutis Biotherapeutics presented fresh clinical data for its topical drug ZORYVE at the EADV and Fall Clinical conferences, adding real‑world evidence on its use for inflammatory skin conditions. The company also received a 2026 Marie Claire Beauty Award for ZORYVE, highlighting its potential beyond dermatology. Meanwhile, analysts have downgraded the stock, citing a shrinking valuation multiple. These developments suggest the market is reassessing the company’s growth prospects.